Network Established to Promote Transfection Research

A mutual support network has been formed to encourage research based on transfection of nucleic acids, genes, or a small interfering RNA.
Polyplus-transfection (Strasbourg, France), a company specializing in research, development, and marketing of innovative reagents for drug delivery, gene therapy, and transfection has established a "user group” network to bring together research scientists and clinicians in an international network of users of Polyplus-transfection's gene therapy reagents. The group is called the "Polyplus in vivo Consortium.”
The aim of the consortium is to encourage users of Polyplus-transfection's products and solutions to share their experience and thereby accelerate the implementation of clinical trials. Consortium members will be given access to Polyplus-transfection's latest technology. The company plans to organize regular meetings and workshops and will actively support the members of the consortium in their preclinical and clinical therapeutic projects.
"The Polyplus in vivo Consortium will make research and development of gene therapy applications easier, said Joëlle Bloch, CEO of Polyplus-transfection. "The project meets a real need that was revealed by the first clinical research teams using our products. It will allow Polyplus-transfection to build a true network where users of our transfection reagents can exchange know-how and experience. This network will help our customers get their clinical trials under way and also help Polyplus-transfection develop solutions that suit users' needs.”


Related Links:
Polyplus-transfection